News und Analysen
![Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, April 30, 2020, to discuss its financial and operating
![Drägerwerk: Bombastische Auftragszahlen – was ist jetzt drin?](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Drägerwerk: Bombastische Auftragszahlen – was ist jetzt drin?
Die Produkte des Medizintechnik-Herstellers Drägerwerk (WKN: 555060) sind gefragt wie nie. Das beschert der Firma aus Lübeck, die im Zusammenhang mit der COVID-19-Pandemie einen „gesellschaftlichen
![VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005751/en/
An advanced pipeline of active substances (Graphic
![QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug
![Singapore Researchers Use NanoString’s nCounter Platform to Rapidly Profile the Response of the Immune System to the SARS-CoV-2 Virus](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Singapore Researchers Use NanoString’s nCounter Platform to Rapidly Profile the Response of the Immune System to the SARS-CoV-2 Virus
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the first publication utilizing the nCounter®
![STAAR Surgical to Report First Quarter Results on May 6, 2020](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
STAAR Surgical to Report First Quarter Results on May 6, 2020
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
![Clovis Oncology Announces Debt Exchange Transaction](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Clovis Oncology Announces Debt Exchange Transaction
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on April 14, 2020 it entered into a privately negotiated exchange agreement with a holder of its 2.50% Convertible Senior Notes due 2021
![Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance.
Subject to quarter-end closing adjustments, the Company
![As COVID-19 Pushes Hospital Patients to Post-Acute Care Settings, Supply and Resource Needs Grow, Per Premier Inc. Survey](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
As COVID-19 Pushes Hospital Patients to Post-Acute Care Settings, Supply and Resource Needs Grow, Per Premier Inc. Survey
Senior nursing and assisted living facilities have limited personal protective equipment (PPE) to care for a greater volume of patients, according to a Premier Inc. survey – indicating a second
![ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics
![Agilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Agilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21
Agilent Technologies, Inc. (NYSE: A) today announced that due to the expanded and evolving nature of the COVID-19 pandemic and resulting effects on customer operations, it is withdrawing its
![Hanger Announces Dates of 2020 First Quarter Earnings Release and Conference Call](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Hanger Announces Dates of 2020 First Quarter Earnings Release and Conference Call
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced it will report its financial results for the first quarter ended March
![Epigenomics: Das wird für Rückenwind sorgen!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Epigenomics: Das wird für Rückenwind sorgen!
Epigenomics (WKN: A11QW5) habe „umfassende Maßnahmen zur Kostensenkung“ in allen Unternehmensbereichen eingeleitet, wie es heute mitteilt. Ziel ist die Sicherung von Liquidität in Zeiten von Corona.
![STAAR Surgical Provides COVID-19 Business Update](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
STAAR Surgical Provides COVID-19 Business Update
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided a business update relating to
![MEDICREA Reports 2019 Annual Results and 2020 First Quarter Sales](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
MEDICREA Reports 2019 Annual Results and 2020 First Quarter Sales
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling
![EOS imaging Announces the Rescheduling of the Publication of Its Annual Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
EOS imaging Announces the Rescheduling of the Publication of Its Annual Results
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![QIAGEN Announces Preliminary Q1 2020 Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
QIAGEN Announces Preliminary Q1 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020.
Net sales rose approximately 9% at
![QIAGEN gibt vorläufige Ergebnisse des ersten Quartals 2020 bekannt](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
QIAGEN gibt vorläufige Ergebnisse des ersten Quartals 2020 bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gibt die vorläufigen Umsatzergebnisse und den vorläufigen bereinigten Gewinn je Aktie für das erste Quartal 2020 bekannt.
Der bereinigte
![Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of
![Sangamo Announces Closing of Biogen Collaboration Agreement](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sangamo Announces Closing of Biogen Collaboration Agreement
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global
![Pfizer Advances Battle Against COVID-19 on Multiple Fronts](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer Advances Battle Against COVID-19 on Multiple Fronts
Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across
![Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine
![Portfoliocheck: Mit United Health spielt Andreas Halvorsen die Gesundheitskarte](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Portfoliocheck: Mit United Health spielt Andreas Halvorsen die Gesundheitskarte
![U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment
![Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders
Pfizer Inc. (NYSE: PFE) today announced that its 2020 Annual Meeting of Shareholders will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19